Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Gee Youn (Geeny) Kim, PharmD, Jamie L. Koprivnikar, MD, Rebecca Testi, MSN, RN, APN-C, OCN, Tara McCabe, FNP-C, MSN, RN, BSN, Grace Perry, MSN, RN, APN-C, OCN, Danielle Marcotulli, MSN, RN, FNP-BC, AOCNP, Elizabeth Jones, BSN, RN, OCN, Xue Geng, MS, Ming Tan, James K. McCloskey, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142891

Published: 2020

Journal Articles

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Maher Albitar, Michele L. Donato, MD, David S. Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, James K. McCloskey, MD, Jamie L. Koprivnikar, MD, Andrew Ip, MDMSc, Andre H. Goy, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140049

Published: 2020

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study

Blood (2018) 132 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2018-99-112672

Published: 2018

Journal Articles

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Adam Zrinski Albitar, BS, Neil Shah, MD, James K McCloskey, MD, Jamie L. Koprivnikar, MD, Jianhua Zhao, PhD, Chirag Desai, MS, MBA, Sucha Sudarsanam, MS, Maher Albitar, MD, Catherine E. Lai, MD

Blood (2018) 132 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2018-99-117365

Published: 2018

Journal Articles

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Blood (2018) 132 (Supplement 1): 207.

https://doi.org/10.1182/blood-2018-99-113094

Published: 2018

Journal Articles

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

James K McCloskey, MD, Genique Stanislaus, ANP, Jamie L. Koprivnikar, MD, Tracy Andrews, PhD, Jones Elizabeth, Danielle Marcotulli, APN, Grace Perry, APN, Stuart L. Goldberg, MD, Stefan Faderl

Blood (2017) 130 (Supplement 1): 5050.

https://doi.org/10.1182/blood.V130.Suppl_1.5050.5050

Published: 2017

Journal Articles

TP53 Mutations Determine Outcome of Patients (pts) with High-Risk Myelodysplastic Syndrome (HRMDS) and Acute Myelogenous Leukemia (AML) Regardless of Karyotype and ELN Risk Stratification

James K. McCloskey, MD, Marshall McKenna, BA, Jamie L. Koprivnikar, MD, Samantha Depadova, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 5242.

https://doi.org/10.1182/blood.V128.22.5242.5242

Published: 2016

Journal Articles

Outcome of Acute Myeloid Leukemia (AML) Induction Therapy Based on D14 Marrow Biopsy According to European Leukemia Net (ELN) Risk Classification

David Ray, PharmD, MBA, Jamie L. Koprivnikar, MD, James K. McCloskey, MD, Genique Stanislaus, ANP, Christina Howlett, PharmD, BCOP, Amy Davidow, PhD, Samantha Depadova, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 5174.

https://doi.org/10.1182/blood.V128.22.5174.5174

Published: 2016

Journal Articles

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

James K. McCloskey, MD, Samantha Depadova, Jamie L. Koprivnikar, MD, Tracy Andrews, MA, Marshall McKenna, BA, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 4017.

https://doi.org/10.1182/blood.V128.22.4017.4017

Published: 2016

Journal Articles

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

James K. McCloskey, MD, Jamie L. Koprivnikar, MD, Stuart L. Goldberg, MD, Themba L Nyirenda, PhD, Genique Stanislaus, ANP, Christina Howlett, PharmD, BCOP, Stefan Faderl, MD

Blood (2015) 126 (23): 5168.

https://doi.org/10.1182/blood.V126.23.5168.5168

Published: 2015

Journal Articles

A Single Institution Retrospective Review of Characteristics and Outcomes of Patients Requiring Chronic Dose Reduction of TKIs Given As Front-Line Therapy for Chronic Phase CML

Jamie L. Koprivnikar, MD, James K. McCloskey, MD, Yucai Wang, MD PhD, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2015) 126 (23): 5171.

https://doi.org/10.1182/blood.V126.23.5171.5171

Published: 2015

NARROW

Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

TP53 Mutations Determine Outcome of Patients (pts) with High-Risk Myelodysplastic Syndrome (HRMDS) and Acute Myelogenous Leukemia (AML) Regardless of Karyotype and ELN Risk Stratification

Outcome of Acute Myeloid Leukemia (AML) Induction Therapy Based on D14 Marrow Biopsy According to European Leukemia Net (ELN) Risk Classification

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

A Single Institution Retrospective Review of Characteristics and Outcomes of Patients Requiring Chronic Dose Reduction of TKIs Given As Front-Line Therapy for Chronic Phase CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only